Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Effectiveness of Methylphenidate Late Formula to Reduce Cannabis Use in Young Cannabis-Related Patients and Attention Deficit Disorder Hyperactivity
Brief Summary: Abuse of psychoactive substances is a behavior belonging to the field of risk behaviors that begins and takes place during adolescence. These risk behaviors are a major public health problem in France and worldwide.

Cannabis is the first illicit drug consumed by adolescents in France. His experimentation progresses rapidly between 11 and 17 years. The relationship between cannabis use and mental health has been shown by several studies. In particular Attention Deficit Hyperactivity Disorder (ADHD), characterized by attention deficit, impulsivity and disabling motor hyperactivity and beginning before 12 years of age (DSM-5), is a major risk factor for the consumption of cannabis. ADHD is a common condition (9% of children and 5% of adults), but often undiagnosed or untreated. It has been shown that the treatment of ADHD in childhood protects the consumption of psychoactive products during adolescence or adulthood. However, to our knowledge there is no study showing that treatment with methylphenidate in an ADHD patient - not treated - but already a cannabis user, was a positive prognostic factor in the decrease in cannabis use.


Options:
A: Arm Label: Methylphenidate; Type: EXPERIMENTAL; Interventions: Drug: Methylphenidate | Arm Label: Matching Placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: Matching Placebo | Intervention Type: DRUG; Name: Methylphenidate; Assigned to Arm(s): Methylphenidate | Intervention Type: OTHER; Name: Matching Placebo; Assigned to Arm(s): Matching Placebo
B: Arm Label: 001; Type: EXPERIMENTAL; Interventions: Drug: open label PR OROS methylphenidate | Arm Label: 002; Type: EXPERIMENTAL; Interventions: Drug: double blind PR OROS methylphenidate | Arm Label: 003; Type: PLACEBO_COMPARATOR; Interventions: Drug: double blind placebo | Intervention Type: DRUG; Name: double blind placebo; Assigned to Arm(s): 003 | Intervention Type: DRUG; Name: double blind PR OROS methylphenidate; Assigned to Arm(s): 002 | Intervention Type: DRUG; Name: open label PR OROS methylphenidate; Assigned to Arm(s): 001
C: N/A
D: Arm Label: 001; Type: EXPERIMENTAL; Interventions: Drug: JNJ-31001074 1 mg/d | Arm Label: 002; Type: EXPERIMENTAL; Interventions: Drug: JNJ-31001074 3 mg/d | Arm Label: 003; Type: EXPERIMENTAL; Interventions: Drug: JNJ-31001074 10 mg/d | Arm Label: 004; Type: ACTIVE_COMPARATOR; Interventions: Drug: Atomoxetine 80 mg/d | Arm Label: 005; Type: ACTIVE_COMPARATOR; Interventions: Drug: OROS methylphenidate HCl 54 mg/d | Arm Label: 006; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Atomoxetine 80 mg/d; Assigned to Arm(s): 004 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 006 | Intervention Type: DRUG; Name: OROS methylphenidate HCl 54 mg/d; Assigned to Arm(s): 005 | Intervention Type: DRUG; Name: JNJ-31001074 3 mg/d; Assigned to Arm(s): 002 | Intervention Type: DRUG; Name: JNJ-31001074 1 mg/d; Assigned to Arm(s): 001 | Intervention Type: DRUG; Name: JNJ-31001074 10 mg/d; Assigned to Arm(s): 003

Answer: A